title: Evaluation of the GenoType® MTBDRsl assay in Korean patients with MDR or XDR tuberculosis.
abstract: BACKGROUND
  This study used the GenoType® MTBDRsl assay (MTBDRsl, Hain Lifescience, Nehren, Germany), an assay for anti-tuberculosis drug susceptibility testing, for the detection of resistance of 40 tuberculosis strains to fluroquinolones (FLQ), injectable drugs (amikacin or capreomycin) and ethambutol to identify multi-drug resistant and extensively drug-resistant tuberculosis patients previously identified by solid drug susceptibility test (DST).
  
  
  METHODS
  These tuberculosis strains were analysed by both DNA sequencing and conventional drug susceptibility testing on solid medium.
  
  
  RESULTS
  The overall agreement rates of the MTBDRsl assay and phenotypic drug susceptibility testing for the detection of ofloxacin (OXF), moxifloxacin (MXF), amikacin (AMK), capreomycin (CPM) and ethambutol (EMB) susceptibility in clinical strains were 87.5% (35/40), 87.5% (35/40), 97.5% (39/40), 60.0% (24/40) and 65.0% (26/40), respectively.
  
  
  CONCLUSIONS
  This study reconfirmed 37 extensively drug-resistant tuberculosis strains using the MTBDRsl assay and these strains were verified by phenotypic drug susceptibility testing. After identification with the MTBDRsl assay, the results were analysed by DNA sequencing with specific primers. From the various mutations identified in the DNA sequencing results, this study found new mutations that characterised EMB-resistant strains, namely, R507K and G406T mutations, which had not been previously reported.
authors.affiliation: a Korean Institute of Tuberculosis , Osong, Cheongju , Chungcheongbuk-do , Republic of Korea ;|b Institutes of Entrepreneurial BioConvergence, Seoul National University , Seoul , Republic of Korea ;|c Program of Nano Science and Technology, Graduate School of Convergence Science and Technology , Seoul National University , Seoul , Republic of Korea ;
authors.forename: Hyun Yong
authors.initials: HY
authors.lastname: Jeong
authors.affiliation: a Korean Institute of Tuberculosis , Osong, Cheongju , Chungcheongbuk-do , Republic of Korea ;
authors.forename: Haeun
authors.initials: H
authors.lastname: Kim
authors.affiliation: b Institutes of Entrepreneurial BioConvergence, Seoul National University , Seoul , Republic of Korea ;|c Program of Nano Science and Technology, Graduate School of Convergence Science and Technology , Seoul National University , Seoul , Republic of Korea ;|d School of Electrical Engineering and Computer Science , Seoul National University , Seoul , Republic of Korea.
authors.forename: Sunghoon
authors.initials: S
authors.lastname: Kwon
authors.affiliation: a Korean Institute of Tuberculosis , Osong, Cheongju , Chungcheongbuk-do , Republic of Korea ;
authors.forename: Sungweon
authors.initials: S
authors.lastname: Ryoo
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D054908:Extensively Drug-Resistant Tuberculosis / Q000382:microbiology*; D006801:Humans; D058889:Molecular Typing / Q000379:methods*; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics*
chemical_list: D000995:Antitubercular Agents
keywords: GenoType® MTBDRsl; MDR; XDR; anti-tuberculosis drug susceptibility testing; tuberculosis